Dallas, TX (PRWEB) November 23, 2012
The governments drive to support local production and reduce the countrys reliance on imports, in addition to global epidemiological and demographic trends are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care. BMI believes this will be rectified through the creation of the National Health Insurance scheme over the next decade, but in the meantime unemployment, lack of education and geographical inaccessibility to healthcare for the wider population will continue to hinder growth in the market.
Headline Expenditure Projections Pharmaceuticals: ZAR27.19bn (US$ 3.74bn) in 2011 to ZAR29.61bn (US$ 3.61bn) in 2012; +8.9% in local currency and -3.5% in US dollar terms. Healthcare: ZAR261.51bn (US$ 36.01bn) in 2011 to ZAR285.26bn (US$ 34.79bn) in 2012; +9.1% in local currency terms and -3.4% in US dollar terms. Medical devices: ZAR11.43bn (US$ 1.57bn) in 2011 to ZAR12.19bn (US$ 1.49bn) in 2012; +6.7% in local currency terms and -5.5% in US dollar terms. Forecast changed due to depreciation of the South African rand.
Product Description
The South Africa Pharmaceuticals & Healthcare Report features Espicoms forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
Espicoms South Africa Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Africa pharmaceutical and healthcare industry.
Key Benefits